<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335725</url>
  </required_header>
  <id_info>
    <org_study_id>01GBF/FSH08</org_study_id>
    <nct_id>NCT00335725</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.</brief_title>
  <official_title>Multicentric Prospective, Randomised, Controlled Clinical Study on Clinical Efficacy and Tolerability of Urinary FSH (Fostimon® , IBSA) Versus r-FSH (Gonal-F®, Serono) in ICSI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <brief_summary>
    <textblock>
      Purpose of the study is the comparative evaluation of the clinical efficacy and of the
      general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs
      Gonal-F® Serono) when administered in patients undergoing ICSI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric, prospective, randomised, investigator blind, controlled clinical
      trial (phase III) of two parallel groups, one receiving the test drug FSH (Fostimon® , IBSA)
      and the other the reference drug FSH (Gonal-F®, Serono). The groups will be paired on the
      major prognostic criteria.

      In effect, a double blind trial is not really feasible since the drugs presentations are very
      different. However, in IVF, drugs are usually dispensed and/or injected by a nurse and
      therefor the Investigator can be blind. Moreover, the used preparations will contain the same
      amount of gonadotrophin units (75 IU), will be repackaged in anonymous boxes and the
      following sentence will be written in the Patient Information Sheet: &quot;You are required not to
      inform the Investigator about the product's name&quot;.

      The randomisation is necessary to get groups as comparable as possible for all the other
      aspects. The multicentric design has the double interest of facilitating the patients'
      recruitment and of decreasing the biases related to attitudes in a specific centre.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Oocytes Retrieved</measure>
    <time_frame>10 days after stimulation start</time_frame>
    <description>Total number of oocytes retrieved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>6 weeks after treatment start</time_frame>
    <description>clinical pregnancy rate defined as the presence of gestation sac and heart beat.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Fostimon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostimon is an highly purified FSH preparation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gonal-F is a recombinant FSH preparation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follicle Stimulating Hormone</intervention_name>
    <description>subcutaneous injection of FSH. Starting dose: 225 IU.</description>
    <arm_group_label>Fostimon</arm_group_label>
    <other_name>highly purified human derived FSH; Fostimon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follicle Stimulating Hormone</intervention_name>
    <description>subcutaneous injection of FSH. Starting dose: 225 IU.</description>
    <arm_group_label>Gonal-F</arm_group_label>
    <other_name>rec FSH; Gonal F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women undergoing ovarian stimulation for IntraCytoplasmic Sperm Injection (ICSI) with the
        following characteristics:

        &gt;/= 18 and &lt; 40 years old BMI between 19 and 30 kg/m2 less than 3 previous completed cycles
        basal FSH level less than 10 IU/l within the 6 months prior to the study

        Exclusion Criteria:

        age &lt; 18 and &gt;/= 40 years primary ovarian failure or women known as poor responders, i.e.
        requiring more than 225 IU of FSH as starting dose in previous treatment cycles or having
        less than 3 oocytes retrieved or with an oestradiol serum concentration &lt; 900 pmol/l (250
        pg/ml) ovarian cysts &gt; 20 mm oocyte donation thawed embryos replacement patients affected
        by pathologies associated with any contraindication of being pregnant ascertained or
        presumptive hypersensitivity to the active principle and/or their ingredients abnormal
        bleeding of undetermined origin uncontrolled thyroid or adrenal dysfunction neoplasias
        severe impairment of the renal and/or hepatic functions women deprived of their freedom by
        administrative or legal decision
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J G Grudzinskas, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Bridge Centre One St Thomas Street London Bridge London SE1 9RY, UK2.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Consulting</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Médecine de la Reproduction</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Américain</name>
      <address>
        <city>Neuilly sur Seine</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Medical School</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hungary</country>
  </location_countries>
  <reference>
    <citation>GEMZELL CA, DICZFALUSY E, TILLINGER G. Clinical effect of human pituitary follicle-stimulating hormone (FSH). J Clin Endocrinol Metab. 1958 Dec;18(12):1333-48.</citation>
    <PMID>13611018</PMID>
  </reference>
  <reference>
    <citation>Thompson CR, Hansen LM. Pergonal (menotropins): a summary of clinical experience in the induction of ovulation and pregnancy. Fertil Steril. 1970 Dec;21(12):844-53.</citation>
    <PMID>5481991</PMID>
  </reference>
  <reference>
    <citation>Oelsner G, Serr DM, Mashiach S, Blankstein J, Snyder M, Lunenfeld B. The study of induction of ovulation with menotropins: analysis of results of 1897 treatment cycles. Fertil Steril. 1978 Nov;30(5):538-44.</citation>
    <PMID>720642</PMID>
  </reference>
  <reference>
    <citation>Schwartz M, Jewelewicz R, Dyrenfurth I, Tropper P, Vande Wiele RL. The use of human menopausal and chorionic gonadotropins for induction of ovulation. Sixteen years' experience at the Sloane Hospital for Women. Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 1):801-7.</citation>
    <PMID>6778212</PMID>
  </reference>
  <reference>
    <citation>Notation AD, Tagatz GE, Steffes MW. Serum 17beta-estradiol. Index of follicular maturation during gonadotropin therapy. Obstet Gynecol. 1978 Feb;51(2):204-9.</citation>
    <PMID>622235</PMID>
  </reference>
  <reference>
    <citation>Doré PC, Rice C, Killick S. Human gonadotrophin preparations. May cause allergic reaction. BMJ. 1994 Jun 4;308(6942):1509.</citation>
    <PMID>8019294</PMID>
  </reference>
  <reference>
    <citation>Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod. 1994 Mar;9(3):424-30.</citation>
    <PMID>8006130</PMID>
  </reference>
  <reference>
    <citation>Wikland M, Borg J, Hamberger L, Svalander P. Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum Reprod. 1994 Aug;9(8):1430-6.</citation>
    <PMID>7989500</PMID>
  </reference>
  <reference>
    <citation>Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum Reprod. 1999 Sep;14(9):2207-15.</citation>
    <PMID>10469682</PMID>
  </reference>
  <reference>
    <citation>Remorgida V, Venturini PL, Anserini P, Lanera P, De Cecco L. Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease: hormonal evaluations and clinical perspectives. Am J Obstet Gynecol. 1989 Jan;160(1):108-13.</citation>
    <PMID>2492145</PMID>
  </reference>
  <reference>
    <citation>Hackelöer BJ, Fleming R, Robinson HP, Adam AH, Coutts JR. Correlation of ultrasonic and endocrinologic assessment of human follicular development. Am J Obstet Gynecol. 1979 Sep 1;135(1):122-8.</citation>
    <PMID>474642</PMID>
  </reference>
  <reference>
    <citation>Venturoli S, Paradisi R, Fabbri R, Magrini O, Porcu E, Flamigni C. Comparison between human urinary follicle-stimulating hormone and human menopausal gonadotropin treatment in polycystic ovary. Obstet Gynecol. 1984 Jan;63(1):6-11.</citation>
    <PMID>6419189</PMID>
  </reference>
  <reference>
    <citation>Mendelson EB, Bohm-Velez M, Joseph N, Neiman HL. Gynecologic imaging: comparison of transabdominal and transvaginal sonography. Radiology. 1988 Feb;166(2):321-4.</citation>
    <PMID>3275976</PMID>
  </reference>
  <reference>
    <citation>Fleischer AC. Transabdominal and transvaginal sonography of ovarian masses. Clin Obstet Gynecol. 1991 Jun;34(2):433-42. Review.</citation>
    <PMID>1868645</PMID>
  </reference>
  <reference>
    <citation>Wang CF, Gemzell C. The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertil Steril. 1980 May;33(5):479-86.</citation>
    <PMID>6768596</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2006</study_first_submitted>
  <study_first_submitted_qc>June 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <results_first_submitted>February 12, 2015</results_first_submitted>
  <results_first_submitted_qc>March 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2015</results_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <keyword>Ovarian stimulation</keyword>
  <keyword>Infertility</keyword>
  <keyword>ICSI</keyword>
  <keyword>FSH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fostimon</title>
          <description>Highly purified FSH</description>
        </group>
        <group group_id="P2">
          <title>Gonal-f</title>
          <description>Recombinant FSH</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fostimon</title>
        </group>
        <group group_id="B2">
          <title>Gonal-f</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" spread="4.0"/>
                    <measurement group_id="B2" value="30.0" spread="3.6"/>
                    <measurement group_id="B3" value="30.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>basal FSH</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="2.5"/>
                    <measurement group_id="B2" value="6.0" spread="1.9"/>
                    <measurement group_id="B3" value="6.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Oocytes Retrieved</title>
        <description>Total number of oocytes retrieved</description>
        <time_frame>10 days after stimulation start</time_frame>
        <population>patients who started the stimulation with FSH</population>
        <group_list>
          <group group_id="O1">
            <title>Fostimon</title>
          </group>
          <group group_id="O2">
            <title>Gonal-f</title>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Oocytes Retrieved</title>
          <description>Total number of oocytes retrieved</description>
          <population>patients who started the stimulation with FSH</population>
          <units>oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="4.9"/>
                    <measurement group_id="O2" value="12.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy Rate</title>
        <description>clinical pregnancy rate defined as the presence of gestation sac and heart beat.</description>
        <time_frame>6 weeks after treatment start</time_frame>
        <population>patients who started the FSH treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Fostimon</title>
          </group>
          <group group_id="O2">
            <title>Gonal-F</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate</title>
          <description>clinical pregnancy rate defined as the presence of gestation sac and heart beat.</description>
          <population>patients who started the FSH treatment</population>
          <units>percentage of treated patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fostimon</title>
        </group>
        <group group_id="E2">
          <title>Gonal-F</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>OHSS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Spontaneous abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>tiredness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>spontaneous abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>IBSA Clinical Research Manager</name_or_title>
      <organization>IBSA instutut Biochimique SA</organization>
      <phone>+41 58 360 1000</phone>
      <email>sd@ibsa.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

